Cantor Fitzgerald maintained its Neutral rating on Pfizer stock, indicating a steady outlook for the pharmaceutical company. The firm's decision suggests no significant change in its assessment of Pfizer's performance.
Cantor Fitzgerald's reiteration of a Neutral rating on Pfizer stock suggests the firm sees no immediate catalyst for significant upside or downside. This implies a balanced view on the pharmaceutical company's current valuation and future prospects.
Cantor Fitzgerald's reiteration of a Neutral rating on Pfizer stock suggests the firm sees no immediate catalyst for significant upside or downside. This implies a balanced view on the pharmaceutical company's current valuation and future prospects.
Pick the topics you care about. Get only what matters, on your cadence.
Trading stocks, CFDs, spread betting, futures, and options involves a high level of risk and may not be suitable for all investors. Prices can move rapidly, and losses can occur quickly and exceed your expectations.
